Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. (2021)
Attributed to:
Evaluating new healthcare technologies in cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.48350/164184
Publication URI: https://boris.unibe.ch/164184/
Type: Other